CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
September 20 2018 - 8:33PM
CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company
focused on developing transformative gene-based medicines for
serious diseases, today announced the pricing of an underwritten
public offering of 4,210,526 common shares at a public offering
price of $47.50 per share, before underwriting discounts. In
addition, underwriters have a 30-day option to purchase up to an
additional 631,578 common shares at the public offering price less
the underwriting discount. CRISPR Therapeutics anticipates its
gross proceeds from the offering, before deducting the underwriter
discounts and commissions and other offering expenses, to be
approximately $200 million, excluding any exercise of the
underwriters’ option to purchase additional shares. The offering is
expected to close on or about September 25, 2018, subject to
customary closing conditions.
Goldman Sachs & Co. LLC, Piper Jaffray & Co., Barclays
Capital Inc. and Wells Fargo Securities, LLC are acting as joint
book-running managers for the offering. Guggenheim Securities, LLC
and Needham & Company, LLC are acting as co-managers for the
offering.
An automatic shelf registration statement on Form S-3ASR (File
No. 333-227427) relating to these securities has been filed with
the Securities and Exchange Commission (SEC) and has become
effective. This press release shall not constitute an offer to sell
or a solicitation of an offer to buy, nor shall there be any sale
of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
A preliminary prospectus supplement relating to and describing
the terms of the offering was filed with the SEC on September 19,
2018. The final prospectus supplement, relating to the offering
will be filed with the SEC and will be available on the SEC’s
website at www.sec.gov. A copy of the final prospectus supplement
may be obtained, when available, from Goldman Sachs & Co. LLC
by mail at 200 West Street, New York, NY 10282, Attention:
Prospectus Department, by telephone at (866) 471-2526, or by email
at prospectus-ny@ny.email.gs.com; from Piper Jaffray & Co.,
Attn: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email
at prospectus@pjc.com; or Barclays Capital Inc., c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
by telephone at (888) 603-5847 or by email at
Barclaysprospectus@broadridge.com; or from Wells Fargo Securities,
LLC, Attn: Equity Syndicate Department, 375 Park Avenue, New York,
New York 10152, or by email at cmclientsupport@wellsfargo.com, or
by telephone at (800) 326-5897.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on
developing transformative gene-based medicines for serious diseases
using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR
Therapeutics AG is headquartered in Zug, Switzerland, with its
wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and
R&D operations based in Cambridge, Massachusetts.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding CRISPR Therapeutics’ anticipated public offering. The
words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release, such as the expected closing date, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions and the satisfaction of customary closing
conditions related to the offering. These and other risks and
uncertainties are described in greater detail in the section
entitled “Risk Factors” in CRISPR Therapeutics’ Annual Report on
Form 10-K for the year ended December 31, 2017, as filed with the
SEC on March 8, 2018, the prospectus supplement related to the
public offering and other filings that CRISPR Therapeutics may make
with the SEC in the future. Any forward-looking statements
contained in this press release represent CRISPR Therapeutics’
views only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date. CRISPR
Therapeutics explicitly disclaims any obligation to update any
forward-looking statements.
CRISPR Investor Contact:Susan
Kim617-307-7503susan.kim@crisprtx.com
CRISPR Media Contact:Jennifer Paganelli WCG on behalf of CRISPR
347-658-8290jpaganelli@wcgworld.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2024 to May 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From May 2023 to May 2024